Table 2.
Cost analysis for introduction of serum fms‐like tyrosine kinase‐1/placental growth factor (sFlt‐1/PlGF) ratio test in addition to current diagnostic procedures (test scenario) compared with costs of current diagnostic procedures only (no‐test scenario), for guiding management of pre‐eclampsia (PE) in a cohort of 1050 women with suspected PE from the PROGNOSIS study
| Treatment | No‐test scenario cost (£) | Test scenario cost (£) | Difference (£) |
|---|---|---|---|
| Initial appointment | 445 673 | 445 673 | 0 |
| sFlt‐1/PlGF test | — | 68 250 | 68 250 |
| sFlt‐1/PlGF retest | — | 40 043 | 40 043 |
| Management costs prior to PE for patients who develop PE | 399 103 | 422 755 | 23 652 |
| Low risk | 25 629 | 25 506 | −123 |
| Intermediate risk | 77 169 | 126 907 | 49 738 |
| High risk | 296 306 | 270 343 | −25 963 |
| PE management | 616 337 | 609 049 | −7288 |
| Management costs for patients without PE | 2 811 942 | 2 326 603 | −485 340 |
| Low risk | 304 432 | 351 135 | 46 703 |
| Intermediate risk | 916 656 | 1 273 271 | 356 616 |
| High risk | 1 590 855 | 702 196 | −888 658 |
| Use of corticosteroids | 2737 | 2237 | −500 |
| Unplanned re‐attendance at hospital | 69 591 | 69 591 | — |
| Total per cohort | 4 345 382 | 3 984 200 | −361 182 |
| Total per patient | 4138 | 3794 | −344 |
Slight discrepancies between numbers and totals are due to rounding.